Efficacy News and Research

RSS
CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Psychotherapies have specific effects on psychosis symptoms

Psychotherapies have specific effects on psychosis symptoms

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

New score ‘reliable and valid’ for neurogenic bladder dysfunction

New score ‘reliable and valid’ for neurogenic bladder dysfunction

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Commonly-used HIV drug kills HPV that leads to cervical cancer

Commonly-used HIV drug kills HPV that leads to cervical cancer

Research findings may help combat MRSA

Research findings may help combat MRSA

Research findings have important implications for personalized treatment of alcohol abuse

Research findings have important implications for personalized treatment of alcohol abuse

Mobile compression device just as effective as blood thinners in preventing DVT after joint surgery

Mobile compression device just as effective as blood thinners in preventing DVT after joint surgery

Research roundup: Examining readmissions; easing doctor burnout

Research roundup: Examining readmissions; easing doctor burnout

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.